Uraki Shinsuke, Ariyasu Hiroyuki, Doi Asako, Furuta Hiroto, Nishi Masahiro, Usui Takeshi, Yamaue Hiroki, Akamizu Takashi
The 1st Department of Internal Medicine, Wakayama Medical University, WakayamaJapan.
Department of Medical Genetics, Shizuoka General Hospital, Shizuoka CityJapan.
Endocrinol Diabetes Metab Case Rep. 2017 Apr 6;2017. doi: 10.1530/EDM-17-0027. eCollection 2017.
A 54-year-old man had gastrinoma, parathyroid hyperplasia and pituitary tumor. His family history indicated that he might have multiple endocrine neoplasia type 1 (MEN1). gene analysis revealed a heterozygous germline mutation (Gly156Arg). Therefore, we diagnosed him with MEN1. Endocrinological tests revealed that his serum prolactin (PRL) and plasma adrenocorticotropic hormone (ACTH) levels were elevated to 1699 ng/mL and 125 pg/mL respectively. Immunohistochemical analysis of the resected pancreatic tumors revealed that the tumors did not express ACTH. Overnight 0.5 and 8 mg dexamethasone suppression tests indicated that his pituitary tumor was a PRL-ACTH-producing plurihormonal tumor. Before transsphenoidal surgery, cabergoline was initiated. Despite no decrease in the volume of the pituitary tumor, PRL and ACTH levels decreased to 37.8 ng/mL and 57.6 pg/mL respectively. Owing to the emergence of metastatic gastrinoma in the liver, octreotide was initiated. After that, PRL and ACTH levels further decreased to 5.1 ng/mL and 19.7 pg/mL respectively. He died from liver dysfunction, and an autopsy of the pituitary tumor was performed. In the autopsy study, histopathological and immunohistochemical (IHC) analysis showed that the tumor was single adenoma and the cells were positive for ACTH, growth hormone (GH), luteinizing hormone (LH) and PRL. RT-PCR analysis showed that the tumor expressed mRNA encoding all anterior pituitary hormones, pituitary transcription factor excluding estrogen receptor (ER) β, somatostatin receptor (SSTR) 2, SSTR5 and dopamine receptor D (D2R). PRL-ACTH-producing tumor is a very rare type of pituitary tumor, and treatment with cabergoline and octreotide may be useful for controlling hormone levels secreted from a plurihormonal pituitary adenoma, as seen in this case of MEN1.
Although plurihormonal pituitary adenomas were reported to be more frequent in patients with MEN1 than in those without, the combination of PRL and ACTH is rare.RT-PCR analysis showed that the pituitary tumor expressed various pituitary transcription factors and IHC analysis revealed that the tumor was positive for PRL, ACTH, GH and LH.Generally, the effectiveness of dopamine agonist and somatostatin analog in corticotroph adenomas is low; however, if the plurihormonal pituitary adenoma producing ACTH expresses SSTR2, SSTR5 and D2R, medical therapy for the pituitary adenoma may be effective.
一名54岁男性患有胃泌素瘤、甲状旁腺增生和垂体瘤。他的家族史表明他可能患有1型多发性内分泌腺瘤病(MEN1)。基因分析显示存在杂合性种系突变(Gly156Arg)。因此,我们诊断他患有MEN1。内分泌检查显示他的血清催乳素(PRL)和血浆促肾上腺皮质激素(ACTH)水平分别升高至1699 ng/mL和125 pg/mL。对切除的胰腺肿瘤进行免疫组织化学分析显示,肿瘤不表达ACTH。过夜0.5 mg和8 mg地塞米松抑制试验表明,他的垂体瘤是一种产生PRL-ACTH的多激素肿瘤。在经蝶窦手术前,开始使用卡麦角林。尽管垂体瘤体积没有减小,但PRL和ACTH水平分别降至37.8 ng/mL和57.6 pg/mL。由于肝脏出现转移性胃泌素瘤,开始使用奥曲肽。此后,PRL和ACTH水平进一步分别降至5.1 ng/mL和19.7 pg/mL。他死于肝功能不全,并对垂体瘤进行了尸检。在尸检研究中,组织病理学和免疫组织化学(IHC)分析显示肿瘤为单发性腺瘤,细胞对ACTH、生长激素(GH)、黄体生成素(LH)和PRL呈阳性。逆转录聚合酶链反应(RT-PCR)分析显示,肿瘤表达编码所有垂体前叶激素的mRNA、不包括雌激素受体(ER)β的垂体转录因子、生长抑素受体(SSTR)2、SSTR5和多巴胺受体D(D2R)。产生PRL-ACTH的肿瘤是一种非常罕见的垂体瘤类型,如本MEN1病例所示,使用卡麦角林和奥曲肽治疗可能有助于控制多激素垂体腺瘤分泌的激素水平。
虽然据报道MEN1患者中多激素垂体腺瘤比非MEN1患者更常见,但PRL和ACTH同时出现的情况很少见。RT-PCR分析显示垂体瘤表达多种垂体转录因子,IHC分析显示肿瘤对PRL、ACTH、GH和LH呈阳性。一般来说,多巴胺激动剂和生长抑素类似物对促肾上腺皮质激素腺瘤的疗效较低;然而,如果产生ACTH的多激素垂体腺瘤表达SSTR2、SSTR5和D2R,垂体腺瘤的药物治疗可能有效。